187 related articles for article (PubMed ID: 34627166)
21. Cost-effectiveness analyses using real-world data: an overview of the literature.
Bowrin K; Briere JB; Levy P; Millier A; Clay E; Toumi M
J Med Econ; 2019 Jun; 22(6):545-553. PubMed ID: 30816067
[No Abstract] [Full Text] [Related]
22. Network Meta-analysis on Disconnected Evidence Networks When Only Aggregate Data Are Available: Modified Methods to Include Disconnected Trials and Single-Arm Studies while Minimizing Bias.
Thom H; Leahy J; Jansen JP
Med Decis Making; 2022 Oct; 42(7):906-922. PubMed ID: 35531938
[TBL] [Abstract][Full Text] [Related]
23. Incorporating single-arm studies in meta-analysis of randomised controlled trials: a simulation study.
Singh J; Abrams KR; Bujkiewicz S
BMC Med Res Methodol; 2021 Jun; 21(1):114. PubMed ID: 34082702
[TBL] [Abstract][Full Text] [Related]
24. Use of Structured Template and Reporting Tool for Real-World Evidence for Critical Appraisal of the Quality of Reporting of Real-World Evidence Studies: A Systematic Review.
Khambholja K; Gehani M
Value Health; 2023 Mar; 26(3):427-434. PubMed ID: 36210293
[TBL] [Abstract][Full Text] [Related]
25. Comparison of exclusion, imputation and modelling of missing binary outcome data in frequentist network meta-analysis.
Spineli LM; Kalyvas C
BMC Med Res Methodol; 2020 Feb; 20(1):48. PubMed ID: 32111167
[TBL] [Abstract][Full Text] [Related]
26. An empirical comparison of Bayesian modelling strategies for missing binary outcome data in network meta-analysis.
Spineli LM
BMC Med Res Methodol; 2019 Apr; 19(1):86. PubMed ID: 31018836
[TBL] [Abstract][Full Text] [Related]
27. Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants.
Camm AJ; Fox KAA
Open Heart; 2018; 5(1):e000788. PubMed ID: 29713485
[TBL] [Abstract][Full Text] [Related]
28. Adjustment for reporting bias in network meta-analysis of antidepressant trials.
Trinquart L; Chatellier G; Ravaud P
BMC Med Res Methodol; 2012 Sep; 12():150. PubMed ID: 23016799
[TBL] [Abstract][Full Text] [Related]
29. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
[TBL] [Abstract][Full Text] [Related]
30. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
31. Interventions for the management of malignant pleural effusions: a network meta-analysis.
Clive AO; Jones HE; Bhatnagar R; Preston NJ; Maskell N
Cochrane Database Syst Rev; 2016 May; 2016(5):CD010529. PubMed ID: 27155783
[TBL] [Abstract][Full Text] [Related]
32. Translational hurdles with cannabis medicines.
Graham M; Lucas CJ; Schneider J; Martin JH; Hall W
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1325-1330. PubMed ID: 32281186
[TBL] [Abstract][Full Text] [Related]
33. Which method is best for the induction of labour? A systematic review, network meta-analysis and cost-effectiveness analysis.
Alfirevic Z; Keeney E; Dowswell T; Welton NJ; Medley N; Dias S; Jones LV; Gyte G; Caldwell DM
Health Technol Assess; 2016 Aug; 20(65):1-584. PubMed ID: 27587290
[TBL] [Abstract][Full Text] [Related]
34. Toward a better understanding about real-world evidence.
Liu M; Qi Y; Wang W; Sun X
Eur J Hosp Pharm; 2022 Jan; 29(1):8-11. PubMed ID: 34857642
[TBL] [Abstract][Full Text] [Related]
35. Prior Choices of Between-Study Heterogeneity in Contemporary Bayesian Network Meta-analyses: an Empirical Study.
Rosenberger KJ; Xing A; Murad MH; Chu H; Lin L
J Gen Intern Med; 2021 Apr; 36(4):1049-1057. PubMed ID: 33403620
[TBL] [Abstract][Full Text] [Related]
36. Using RWE research to extend clinical trials in diabetes: An example with implications for the future.
Seeger JD; Nunes A; Loughlin AM
Diabetes Obes Metab; 2020 Apr; 22 Suppl 3(Suppl 3):35-44. PubMed ID: 32250529
[TBL] [Abstract][Full Text] [Related]
37. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
38. Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors.
Willis M; Asseburg C; Neslusan C
Diabetes Res Clin Pract; 2019 Feb; 148():222-233. PubMed ID: 30641163
[TBL] [Abstract][Full Text] [Related]
39. Creating and using real-world evidence to answer questions about clinical effectiveness.
de Lusignan S; Crawford L; Munro N
J Innov Health Inform; 2015 Nov; 22(3):368-73. PubMed ID: 26577427
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
